MENS vs AEYE vs NUVB vs HALO vs NVAX

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 14. 5% for AudioEye, Inc. (AEYE). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Halozyme Therapeutics, Inc. at 25. 5x.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +37. 0%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: HALO returned +570. 7% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Jyong Biotech Ltd. Ordinary Shares's 2. 49β — meaning MENS is approximately 346% more volatile than HALO relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 14. 5% for AudioEye, Inc. (AEYE). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 157.

3% to $12. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MENS (Healthcare) and AEYE (Technology) and NUVB (Healthcare) and HALO (Healthcare) and NVAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MENS is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; HALO is a small-cap high-growth stock; NVAX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.